PhD candidate 'Development and clinical translation of novel 177Lu-PSMA treatment strategies for prostate cancer'
Prostate cancer is one of the most common cancers worldwide and leads to significant morbidity and mortality. While the disease can be cured in early stages, …
- Geert Grooteplein Zuid, Nijmegen, Gelderland
- Tijdelijk contract / Tijdelijke opdracht
- Uren per week:
- 36 - 36 uur
- € 2279 - € 4216 per maand
Prostate cancer is one of the most common cancers worldwide and leads to significant morbidity and mortality. While the disease can be cured in early stages, treatment options for more advanced stages of the disease are sparse and may be accompanied with severe side effects. Our research group develops novel and innovative imaging approaches and treatments to improve the outcome of prostate cancer patients. For this purpose we develop radiolabeled tumor targeting agents that specifically accumulate in prostate cancer lesions and allow radionuclide imaging and treatment of these lesions. These newly developed agents have been extensively tested in vitro in cell cultures and in vivo in animal models. The main focus of this PhD project will be to translate these noval tumor targeting agents into the clinics
One of the most important new therapeutic strategies for prostate cancer is treatment with radioactively labeled small molecules which specifically bind to the prostate-specific membrane antigen (PSMA) which is overexpressed in prostate cancer. So far, this so-called 177Lu-PSMA therapy has shown high efficacy in first trials in prostate cancer patients with advanced disease. In this project, this therapy will be applied personalized after dosimetric analysis in patients with oligo-metastatic disease, to evaluate, if patients with more localized disease could also profit from this therapy. In addition, effects of this therapy on the immune system will be evaluated and combinational treatments will be developed.
Tasks and responsibilities
- Design and perform prospective clinical studies to evaluate the imaging potential and therapeutic efficacy of novel radiolabeled prostate cancer targeting agents (177Lu-PSMA in particular);
- Analyze scientific data;
- Write scientific publications and present findings at scientific meetings;
- Work in a team with other scientists and clinicians to plan, discuss, and perform research in a stimulating environment.
- Masters degree in Medicine, Technical Medicine, (Medical) Biology, Biomedical sciences, Molecular life sciences or equivalent;
- Permit to work with radioactivity (or willing to obtain this permit);
- Well-developed communicational and social skills directed towards working in a team;
- Enthusiastic and strong motivation to successfully complete a PhD.
ConditionsSalary is depending on educational background and relevant experience in scale 10A (max € 2.919 gross per month) or scale 10 (max € 4.216 gross per month) Cao umc plus additional vacation bonus (8% per year) and end of year payments (8.3% per year).
Upon commencement of employment we require a certificate of conduct (Verklaring Omtrent het Gedrag, VOG) and there will be a screening based on the provided CV. Radboud university medical center's HR Department will apply for this certificate on your behalf.
Read more about the Radboudumc employment conditions and what our International Office can do for you when moving to the Netherlands.
Additional informationAll additional information about the vacancy can be obtained from Dr. Susanne Lütje, postdoc. Use the Apply button to submit your application.
Please apply before June, 22.
Recruitment agencies are asked not to respond to this job posting.